Clinical trials: Human Cancers
Lung Cancer, Cancer
Bintrafusp Alfa Program Rollover Study
This study is designed to provide continuous access to treatment with bintrafusp alfa for eligible participants from ongoing bintrafusp alfa parent studies (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706…
- Trial name
- NCT05061823
- Testing
- Bintrafusp alfa
- Where
- 21 sites in United States, Belgium and 10 more
- Volunteers
- 22 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Breast Cancer Female, Infertility, Female
Impact of Breast Cancer on Human Folliculogenesis
Advances in cancer diagnosis and treatments have improved the 5-year survival rate for patients over the last decade. Nevertheless, cancer treatments frequently alter patient's fertility, thus compromising their ability to…
- Trial name
- FERTICAN (NCT07148141)
- Testing
- Ovarian stimulation
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Condylomata Acuminata
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
The summary of this study is to know which HPV types are present in genital warts in Argentinean population.
- Trial name
- NCT01598779
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Buenos Aires
Malignant Mesothelioma
The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients.
- Trial name
- NCT01655888
- Testing
- Tremelimumab
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Non-Small Cell Lung Cancer
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then…
- Trial name
- NCT00918203
- Testing
- Olaratumab, Paclitaxel, Carboplatin
- Where
- 23 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- Eli Lilly and Company
Cervical Cancer, Low-grade Squamous Intraepithelial Lesion,
A Multi-center Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal Follow-up of LSIL Cases
The aims of this study are: 1. Surveillance of the prevalence of HPV infection in ASCUS, AGCUS and SIL cases pooled from medical centers in Taiwan and analysis of the related epidemiological factors. 2.
- Conditions
- Cervical Cancer, Low-grade Squamous Intraepithelial Lesion,, Human Papillomavirus
- Trial name
- NCT00201370
- Where
- 4 sites in Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients…
- Trial name
- NCT05268666
- Testing
- JBI-802
- Where
- 4 sites in United States
- Volunteers
- 126 people
- Sponsor
- Jubilant Therapeutics Inc.
Cervical Cancers, CIN - Cervical Intraepithelial Neoplasia
Primary HPV Self-Collection in Indonesia
The purpose of this study is to implement human papillomavirus (HPV) self-collection in Indonesia.
- Conditions
- Cervical Cancers, CIN - Cervical Intraepithelial Neoplasia, Human Papillomavirus (HPV)
- Trial name
- NCT06942286
- Testing
- HPV Self-Collection
- Where
- 3 sites in Indonesia
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Dharmais National Cancer Center Hospital
Anogenital Warts, Condylomata Acuminata
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).
- Conditions
- Anogenital Warts, Condylomata Acuminata, Human Papillomavirus Infection
- Trial name
- NCT01532102
- Testing
- AP611074
- Where
- 4 sites in Argentina, France
- Volunteers
- 24 people
- Sponsor
- Anaconda Pharma
Chronic Hepatitis C, Chronic Hepatitis B
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study
This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC).
- Trial name
- ROLFH (NCT01831037)
- Testing
- Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
- Where
- 4 sites in United States, Canada
- Sponsor
- University of Arkansas
Metastatic Breast Cancer
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
The primary objective for the study is as follows: For the Phase 1b - to determine safety tolerability and recommended Phase 2 dose (RP2D) of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase…
- Trial name
- NCT02753595
- Testing
- Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eisai Inc.
Metastatic Cancer, Epithelial Tumor
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
- Trial name
- STAR (NCT04053283)
- Testing
- NG-641
- Where
- 6 sites in United States
- Volunteers
- 186 people
- Sponsor
- Akamis Bio
Large B-cell Lymphoma
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
This is a study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) in participants aged 18 to < 80 years of age with previously untreated large B-cell…
- Trial name
- Soundtrack D3 (NCT07911553)
- Testing
- Surovatamig, Rituximab, Cyclophosphamide
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Human Papillomavirus Infection
Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka
This PMS study aims to collect safety and reactogenicity data of Cervarix in the local population as per the licensing requirement of the Sri Lankan regulatory authority.
- Trial name
- NCT01551537
- Testing
- Cervarix data collection, Data Collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sarcoma
Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
RATIONALE: Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01426945
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 77 people
- Sponsor
- Children's Oncology Group
Prostate Cancer
Conventional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients
In this observational study the investigators will undertake imaging studies on men with prostate cancer. The primary hypothesis is that ultrasound spectroscopy could be used to determine the extent of disease inside and outside…
- Trial name
- NCT01401972
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
In the phase I part, to determine the recommended doses (RD) and dosing regimens of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive…
- Trial name
- NeoB-Cap1 (NCT06247995)
- Testing
- [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine
- Where
- 28 sites in United States, Australia and 11 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is a single-center, open clinical study, divided into two phases of dose escalation and dose expansion, to observe the safety and efficacy of RD140 injection at different doses in patients with relapsed/refractory multiple…
- Trial name
- NCT06655519
- Testing
- CAR-T（RD140 injection）
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
Cervical Carcinoma, Human Papillomavirus Infection
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention.
- Trial name
- NCT07281430
- Testing
- Biospecimen Collection, Cervical Biopsy, Colposcopy
- Where
- 18 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
- Trial name
- NCT06921837
- Testing
- BDC-4182
- Where
- 16 sites in Australia, South Korea and 1 more
- Volunteers
- 122 people
- Sponsor
- Bolt Biotherapeutics, Inc.